This study not only provided a high-throughput methodology for the discovery of additional inducers of human HO-1, but also identified SRI-37618 as a promising therapeutic candidate to be optimized for clinical use as either a prophylactic or a therapeutic for AKI. Here, HMOX1 is linked to acute kidney injury.